Huons Global, 2Q Sales 143.7 Billion KRW and Operating Profit 19.5 Billion KRW

[Asia Economy Reporter Lee Chun-hee] Huons Global announced on the 17th that its consolidated sales for the second quarter of this year reached 143.7 billion KRW, a 14% increase compared to the same period last year, while operating profit decreased by 11% to 19.5 billion KRW.

A Huons Global official explained, "Operating profit slightly declined due to increased research and development (R&D) investments in the first half of the year aimed at securing future growth engines for some of our key subsidiaries."

The key subsidiary Huons recorded consolidated sales of 111.1 billion KRW and operating profit of 12.6 billion KRW, showing a 7% increase in sales and a 5% decrease in operating profit compared to the same period last year, supported by expanded exports to the U.S. of health functional foods, local anesthetics, and low dead space (LDS) vaccine syringes.

Humedics maintained a stable growth trend in its beauty business centered on a portfolio including fillers, botulinum toxin, and medical devices. In particular, the disposable eye drop consignment business also contributed new sales, resulting in increases in both sales and operating profit. Consolidated sales amounted to 25.8 billion KRW, up 18%, and operating profit reached 3.7 billion KRW, a 10% growth compared to the same period last year.

Newly incorporated subsidiary Huons Blossom succeeded in turning a profit with sales of 3.8 billion KRW and operating profit of 400 million KRW. Huons Biopharma, established through a physical division in April, recorded sales of 3.2 billion KRW and operating profit of 600 million KRW.

This content was produced with the assistance of AI translation services.